CJC-1295 NO DAC + Ipamorelin (5 mg + 5 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection daily, typically before bed or on waking, held to the same time each day because ipamorelin has a half-life of roughly 1.5 to 2.5 hours and its GH pulse peaks around 40 minutes after the dose. Every figure in the table is computed at the reconstitution used here: 10 mg of blend in 2.0 mL gives 5 mg/mL of total peptide, so on a U-100 syringe 1 unit is 0.01 mL and delivers 50 mcg of blend, which is 25 mcg of CJC-1295 (no DAC) plus 25 mcg of ipamorelin. Because doses are quoted per peptide, the unit count is the per peptide dose divided by 25: 100 mcg each is 4 units, 150 mcg each is 6 units, 200 mcg each is 8 units, 250 mcg each is 10 units, and 300 mcg each is 12 units. Nothing in this protocol exceeds 12 units (0.12 mL), so no dose needs splitting into two injections, and a smaller 30 unit or 50 unit insulin barrel is easier to read at these volumes than a full 100 unit barrel. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation.

Results Timeline

Sequence described in the research record. Individual response varies.

• Roughly 40 minutes after each injection: the ipamorelin component drives a rapid GH pulse, while the CJC-1295 (no DAC) component holds the GHRH signal open across the same window.
• Weeks 1 to 2: the starting step at 100 mcg of each peptide, 4 units (0.04 mL), used to gauge tolerance before any increase.
• Weeks 3 to 6: titration in two week steps, 150 mcg each at 6 units (0.06 mL) and then 200 mcg each at 8 units (0.08 mL).
• Weeks 7 to 12: the plateau at 250 to 300 mcg of each peptide, 10 to 12 units (0.10 to 0.12 mL), held to the end of the course.
• Beyond week 12: the course is extended to 16 weeks at the plateau dose if desired, with no further escalation described in the master protocol.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL total (2.5 mg/mL of each peptide), 1 unit = 0.01 mL » 50 mcg of blend on a U-100 insulin syringe, which is 25 mcg of CJC-1295 (no DAC) plus 25 mcg of ipamorelin.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F); use within about 28 days; avoid freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• A 10 mg vial reconstituted with 2.0 mL holds 40 doses at the 4 unit starting step and about 17 doses at the 12 unit plateau, so a vial in use is generally finished well inside the 28 day window.

Supplies Needed

Planning below is based on a 12 week daily course with gradual titration, which works out to about 1.4 mg of blend per week during weeks 1 to 2 and about 3.5 to 4.2 mg per week once the week 7 to 12 plateau is reached.

Peptide Vials (CJC-1295 NO DAC + Ipamorelin, per vial):

• A full 12 week titrated course uses roughly 34 to 38 mg of blend, which is about 4 of the 10 mg vials; an 8 week course uses roughly 20 to 21 mg and works out to about 3 vials, and a 16 week course uses roughly 48 to 55 mg and works out to about 5 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, and since the largest dose here is 12 units (0.12 mL) a 30 unit or 50 unit barrel reads more clearly than a 100 unit barrel.
• Full course: 56 syringes across 8 weeks, 84 across 12 weeks, and 112 across 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg blend vial takes 2.0 mL of plain bacteriostatic water, so a single 10 mL bottle reconstitutes 5 vials and covers even a 16 week course on its own.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 14 per week.
• Full course: 112 swabs across 8 weeks, 168 across 12 weeks, and 224 across 16 weeks, so two boxes of 100 cover a course up to 12 weeks and three cover 16 weeks.

Important Notes

Practical considerations for consistency and safety.

• Doses in this protocol are stated per peptide, not per milligram of blend. At 5 mg/mL total, 1 unit delivers 25 mcg of CJC-1295 (no DAC) and 25 mcg of ipamorelin at the same time, so a chart figure of 200 mcg each is an 8 unit draw carrying 400 mcg of blend.
• Use new sterile insulin syringes and dispose of them in a sharps container; every draw in this protocol falls between 4 and 12 units, so a 30 unit or 50 unit syringe improves precision at the low end.
• Rotate injection sites across abdomen, thighs, and upper arms to reduce local irritation, and inject slowly, waiting a few seconds before withdrawing the needle.
• Keep the daily timing consistent. Ipamorelin clears in about 1.5 to 2.5 hours, so a dose taken before bed or on waking anchors the GH pulse to the same point in the day rather than scattering it.
• Document the daily dose, the unit count drawn, and the site used, which keeps titration steps honest and makes an unexpected response easier to trace.
• Regulatory Note: neither CJC-1295 (no DAC) nor ipamorelin has ever held FDA approval for any indication, and both were briefly placed on the FDA Category 2 bulk substances list in 2024 before being removed, leaving the pair in regulatory limbo. WADA prohibits growth hormone secretagogues as a class, so athletes subject to anti-doping testing are advised to avoid this blend. For research use only; not for human consumption.

How This Works

CJC-1295 (no DAC) is a modified GHRH analog, a tetrasubstituted 29 amino acid peptide that stimulates pulsatile GH release from the pituitary, and human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 after subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5 to 2.5 hours that elicits a rapid GH pulse peaking around 40 minutes after the dose, and it selectively increases GH without affecting ACTH, cortisol, or prolactin levels. The two peptides reach the somatotroph through different receptors, the GHRH receptor and the growth hormone secretagogue receptor, which is why combining them may produce synergistic GH release rather than simply more of the same signal.

Benefits & Side Effects

Observations from the published record.

• Supports sustained GH and IGF-1 elevation through pulsatile release patterns rather than a flat, continuously raised level.
• Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation, which separates it from older ghrelin receptor agonists in the same class.
• Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
• Generally well tolerated; possible transient effects include flushing, headache, or injection-site reactions.
• Some individuals report increased appetite, water retention, or tingling sensations, most often during the titration steps.
• Evidence position is modest for both halves of the blend: ipamorelin has pharmacokinetic and pharmacodynamic human data rather than a body composition trial, and CJC-1295 (no DAC) rests largely on GH and IGF-1 response data.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to energy needs, since GH driven protein synthesis needs substrate to act on.
• Combine resistance training and aerobic activity to reinforce the metabolic adaptations the GH pulse supports.
• Prioritize sleep quality, as GH is predominantly released during deep sleep and a bedtime dose is timed to fire into that window.
• Manage stress to support hormonal balance and recovery, and keep the injection time consistent so adherence does not drift.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Teichman SL et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults (J Clin Endocrinol Metab, 2006).
2. Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (Am J Physiol Endocrinol Metab, 2006).
3. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology, 1998).
4. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers (Pharmaceutical Research, 1999).